Artelo Biosciences (ARTL) Competitors $12.24 -0.03 (-0.20%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. CLSD, MRSN, LVTX, KPTI, XLO, AKTX, MAAQ, SNYR, RANI, and DYAIShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Clearside Biomedical (CLSD), Mersana Therapeutics (MRSN), LAVA Therapeutics (LVTX), Karyopharm Therapeutics (KPTI), Xilio Therapeutics (XLO), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), Rani Therapeutics (RANI), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors Clearside Biomedical Mersana Therapeutics LAVA Therapeutics Karyopharm Therapeutics Xilio Therapeutics Akari Therapeutics Mana Capital Acquisition Synergy CHC Rani Therapeutics Dyadic International Clearside Biomedical (NASDAQ:CLSD) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Is CLSD or ARTL more profitable? Artelo Biosciences has a net margin of 0.00% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Clearside Biomedical-818.57% N/A -114.23% Artelo Biosciences N/A -226.99%-164.61% Which has better valuation & earnings, CLSD or ARTL? Artelo Biosciences has lower revenue, but higher earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$1.66M22.33-$34.35M-$0.41-1.16Artelo BiosciencesN/AN/A-$9.83M-$17.94-0.68 Which has more volatility and risk, CLSD or ARTL? Clearside Biomedical has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Does the media favor CLSD or ARTL? In the previous week, Clearside Biomedical had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 3 mentions for Clearside Biomedical and 1 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 1.87 beat Clearside Biomedical's score of 1.02 indicating that Artelo Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Clearside Biomedical Positive Artelo Biosciences Very Positive Do institutionals & insiders believe in CLSD or ARTL? 18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 6.2% of Clearside Biomedical shares are held by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate CLSD or ARTL? Clearside Biomedical presently has a consensus target price of $4.20, indicating a potential upside of 780.50%. Artelo Biosciences has a consensus target price of $25.00, indicating a potential upside of 104.16%. Given Clearside Biomedical's higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60 SummaryClearside Biomedical beats Artelo Biosciences on 9 of the 16 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.57M$3.06B$5.61B$9.56BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-0.6821.5127.9020.10Price / SalesN/A205.32392.4667.55Price / CashN/A42.5736.3258.75Price / Book2.318.338.395.83Net Income-$9.83M-$55.06M$3.25B$259.10M7 Day Performance-16.93%-2.37%-1.61%-2.35%1 Month Performance-7.72%15.92%9.08%9.75%1 Year Performance50.06%5.53%35.49%17.02% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences3.0107 of 5 stars$12.25-0.2%$25.00+104.2%+57.3%$8.57MN/A-0.685CLSDClearside Biomedical2.4307 of 5 stars$0.45-10.5%$4.20+843.6%-59.0%$38.64M$1.66M-1.0930Positive NewsGap DownMRSNMersana Therapeutics3.9317 of 5 stars$6.83-11.3%$130.00+1,803.4%-86.3%$38.39M$40.50M-11.58150News CoverageStock SplitLVTXLAVA Therapeutics2.3557 of 5 stars$1.52+6.3%$3.17+108.3%-27.2%$37.62M$11.98M-1.4660Positive NewsGap UpHigh Trading VolumeKPTIKaryopharm Therapeutics3.759 of 5 stars$4.37+0.5%$37.40+755.8%-73.3%$37.58M$145.24M-0.33380Upcoming EarningsGap UpXLOXilio Therapeutics2.7778 of 5 stars$0.68-2.1%$4.00+486.5%-28.6%$36.08M$6.34M-0.8170News CoverageAKTXAkari Therapeutics2.6142 of 5 stars$1.14+1.3%$5.00+340.5%-74.3%$36.04MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.39-4.2%N/A-26.8%$35.65MN/A0.001SNYRSynergy CHC3.8024 of 5 stars$3.72-1.8%$10.00+168.8%N/A$34.85M$34.83M0.0040News CoverageRANIRani Therapeutics2.4817 of 5 stars$0.55+3.6%$7.33+1,231.2%-81.7%$33.63M$1.03M-0.56110Positive NewsUpcoming EarningsGap DownDYAIDyadic International3.2754 of 5 stars$1.11+0.9%$6.00+440.5%-17.8%$33.10M$3.49M-5.557Positive NewsGap Up Related Companies and Tools Related Companies Clearside Biomedical Alternatives Mersana Therapeutics Alternatives LAVA Therapeutics Alternatives Karyopharm Therapeutics Alternatives Xilio Therapeutics Alternatives Akari Therapeutics Alternatives Mana Capital Acquisition Alternatives Synergy CHC Alternatives Rani Therapeutics Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
